The World Health Organization announced a few days ago that the recombinant new crown vaccine Keweisha developed by China’s CanSino Biological Co., Ltd. has officially passed the WHO emergency use certification. This is the third Chinese new crown vaccine certified by WHO for emergency use after Sinopharm and Kexing vaccine.
The WHO said in a statement that according to the WHO emergency use certification process, the quality, safety, efficacy, risk management plan, program applicability and on-site production of CanSino’s new crown vaccine have been evaluated. “The Emergency Use List Technical Advisory Group convened by WHO and comprised of regulatory experts from around the world determined that the vaccine meets WHO’s standards for protection against 2019-nCoV and that the benefits of the vaccine far outweigh the risks.”
The WHO said the vaccine was 64 percent effective against symptomatic infection with the new coronavirus and 92 percent effective against severe disease.
The CanSino vaccine was previously reviewed by the WHO Strategic Advisory Group of Experts on Immunization, which recommended the use of a single 0.5ml dose of CanSino in all age groups 18 years and older.
Post time: May-27-2022